Milestone Scientific Inc

Milestone Scientific Inc(MLSS)股票分析

$0.302

+0.003 (+0.97%)收盤時

Loading chart…
最高
0.329
開盤
0.310
成交量加權均價
0.31
成交量
90.06K
市值
52.51M
最低
0.300
成交金額
27.95K
企業價值/稅息折舊攤銷前利潤(TTM)
-6.33

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.

AI 分析 of Milestone Scientific Inc (MLSS)

持有

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

分析師評級(1)

上檔空間 +231.13%
買進
1 買進
0 持有
0 賣出
目前: 0.30
最低
1.00
平均
1.00
最高
1.00

Benchmark

2025-11-20

目標價

$1

Speculative Buy

Benchmark

2024-11-20

目標價

$1.25

買進

Benchmark

2024-10-10

目標價

$1.25

買進

估值指標

Milestone Scientific Inc(MLSS)目前預期本益比為 18.21,5 年平均預期本益比為 -8.67。

預期本益比

高估
5 年均值 P/E
-8.67
目前P/E
18.21
高估
4.93
低估
-22.27

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-1.14
目前EV/EBITDA
-6.33
高估
1.51
低估
-3.79

預期股價營收比

低估
5 年均值 P/S
5.64
目前P/S
2.39
高估
8.30
低估
2.98

Alphio AI 對 MLSS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MLSS

$0.99

情境價格

基

基準

基準 · 50%MLSS

$0.88

情境價格

悲

悲觀

悲觀 · 25%MLSS

$0.85

情境價格

事件時間軸

2026-09-29 (ET)

09:30:00

Milestone Scientific Drives Growth in CompuFlo Medical Business

2026-09-08 (ET)

17:30:00

Milestone Scientific Files $45M Mixed Securities Shelf

2026-07-01 (ET)

12:00:00

Markets Mixed as Semiconductor Stocks Slip

09:30:00

Company Reports 300% Revenue Growth in Q2

2026-05-14 (ET)

16:30:00

Dow Rises 370 Points as Markets Optimistic on US-China Talks

資訊

MLSS 常見問題 —— 由 Alphio AI 解答

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

1 analysts cover MLSS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 1.00.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易